Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).

ABSTRACT:

Objective

To determine whether once-daily esomeprazole 40 mg or 20 mg compared with placebo reduces the incidence of peptic ulcers over 26 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA) and who are at risk for ulcer development.

Design

Multinational, randomised, blinded, parallel-group, placebo-controlled trial.

Setting

Cardiology, primary care and gastroenterology centres (n=240).

Patients

Helicobacter pylori-negative patients taking daily low-dose ASA (75-325 mg), who fulfilled one or more of the following criteria: age ≥18 years with history of uncomplicated peptic ulcer; age ≥60 years with either stable coronary artery disease, upper gastrointestinal symptoms and five or more gastric/duodenal erosions, or low-dose ASA treatment in

SUBMITTER: Scheiman JM 

PROVIDER: S-EPMC3088470 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature